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rectal cancer, but thisNeoadjuvant treatment in terms of preoperative radiotherapy reduces local recurrence in
improvement has little if any impact on overall survival. Currentlyperformed optimal quality-controlled total mesorectal excision (TME) surgery for patients
in the trial setting can be associated with very low local recurrence rates of less than 10%
whether the patients receive radiotherapy or not. Hence metastatic disease is now the pre-
dominant issue. The concept of neoadjuvant chemotherapy (NACT) is a potentially attrac-
tive additional or alternative strategy to radiotherapy to deal with metastases. However,
randomised phase III trials, evaluating the addition of oxaliplatin at low doses plus preop-
erative fluoropyrimidine-based chemoradiotherapy (CRT), have in the main failed to show a
significant improvement on early pathological response, with the exception of the German
CAO/ARO/AIO-04 study. The integration of biologically targeted agents into preoperative
CRT has also not fulfilled expectations. The addition of cetuximab appears to achieve rel-
atively low rates of pathological complete responses, and the addition of bevacizumab
has raised concerns for excess surgical morbidity. As an alternative to concurrent chemo-
radiation (which delivers only 5–6 weeks of chemotherapy), potential options include an
induction component of 6–12 weeks of NACT prior to radiotherapy or chemoradiation, or
the addition of chemotherapy after short-course preoperative radiotherapy (SCPRT) or che-
moradiation (defined as consolidation chemotherapy) which utilises the ‘‘dead space’’ of
the interval between the end of chemoradiation and surgery, or delivering chemotherapy
alone without any radiotherapy.
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surgical treatment
Rectal cancer is a very heterogeneous disease with different
prognostic implications and varying outcomes. Historically,
a high local recurrence rate has dominated decision-making.
The need for radiation treatment has become deeply in-
grained in surgical and radiation oncology culture, prompted
by an imperative to avoid local pelvic recurrence at all costs.
Local recurrence can be associated with intractable pelvic
pain, tenesmus, mucinous discharge and intestinal obstruc-
tion, and few patients can be saved [1]. However, recent data
suggest that metastases are now the predominant problem
[2]. In a pooled analysis of 2795 patients recruited in five Euro-pean randomised controlled trials, the 5-year distant metas-
tasis rate was 30.8% [3].
Initially, because of the lack of reliable preoperative imag-
ing, attempts to improve outcomes centred on postoperative
chemoradiation according to pathological staging. With the
emergence of more sophisticated imaging, this strategy has
been extrapolated to the neoadjuvant arena, and validated
by further phase III trials. Management has therefore moved
from a solely surgically treated disease to the current wide-
spread use of neoadjuvant radiation or combined chemother-
apy and radiation therapy.
Over the past 3 decades the neoadjuvant management
philosophy has also evolved independently in different re-
gions of the world. The individual phase III studies performed
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the United Kingdom refinements in surgical technique – i.e.
total mesorectal excision (TME) and extralevator abdomino-
perineal excision (ELAPE) [4,5] coupled with improvements
in the quality of such surgery [6] – and the use of MRI and uni-
versal multidisciplinary team (MDT) discussion, have ensured
that isolated local recurrence is now a rare event in 2012, if
the surgeon can perform a good quality TME, even without
radiotherapy [6]. However, even with expertly performed
TME, the rate of distant recurrence has been documented as
18% in stage II patients and 37% in stage III patients in one
important retrospective series [7].
Recently there has been enthusiasm for integrating more
active systemic chemotherapy to increase down-staging and
response and to lessen the risk of metastatic disease. In
stage III colon cancer adjuvant chemotherapy based on
5-fluorouracil (5FU) reduced the risk of recurrence and pro-
longed survival, and hence has been firmly established and
recommended as adjuvant treatment in patients following
a curative resection [8]. More recent studies have confirmed
that the addition of oxaliplatin to 5FU-based chemotherapy
improves disease-free survival (DFS) [9,10] and overall sur-
vival (OS) [10] in patients with stage III colon cancer
(although rectal cancers within 12 cm of the anal verge were
excluded from these studies). FOLFOX is now considered an
international standard as adjuvant chemotherapy for colon
cancer in stage III disease, although there is still controversy
regarding its use in high-risk stage II colon cancer. Yet the
role of adjuvant chemotherapy in rectal cancer is not as
clear-cut as in stage II and stage III colon cancer, and the
validity of this standard has been questioned in a recent
meta-analysis [11].
In Northern Europe short-course preoperative radiation
therapy (SCPRT) (25 Gy in five fractions) followed by immedi-
ate surgery was evaluated as an adjunct to surgery [12,13].
Early trials showed an improvement in survival [12], and there
have been subsequent consistent reports of lower local recur-
rence rates in randomised trials [14,15]. Yet integration into
routine practice in other parts of the world has always been
slightly tempered by early reports of severe acute and long-
term toxicity [12,13,16].
When directly compared with standard chemoradiother-
apy (CRT), SCPRT shows similar efficacy [17,18]. The recent
TROG 01.04 trial in clinical stage T3 rectal cancer compared
SCPRTwith long-course preoperative CRT [18]. The trial con-
firmed similar outcomes for SCPRT and CRT for distant recur-
rence, overall survival and late effects. After a minimum
follow-up period of 3 years cumulative incidences of local
recurrence at 5 years were 7.5% for SCPRT and 5.7% for CRT
respectively (P = 0.51). For distal tumours, six of 48 SCPRT pa-
tients and one of 31 CRT patients had a local recurrence
(P = 0.21).
In the landmark German l CAO/ARO/AIO – 94 Trial [19] a to-
tal of 823 patients were randomised between preoperative
CRT and postoperative CRT (patients received postoperative
adjuvant chemotherapy in both arms of this trial). Acute
and late toxicities were significantly reduced with the preop-
erative approach, although it should be recognised that a
higher radiation dose was mandated for the postoperative
regimen. Loco-regional failure was only 6% in the preopera-tive arm versus 13% in the postoperative arm. There was,
however, no difference observed in the distant metastases
rate, DFS or OS. This advantage is also supported to some ex-
tent by the National Surgical Adjuvant Breast and Bowel Pro-
ject (NSABP R-03) trial results [20] which showed a statistically
significant improvement in 5-year DFS (65% versus 53%,
P = 0.011) for preoperative therapy (although it included an
additional 6 weeks of neoadjuvant chemotherapy). Both trials
have therefore served to validate the benefit of neoadjuvant
5FU-based chemoradiotherapy for locally advanced rectal
cancer compared with postoperative therapy.
Hence, randomised controlled trials have unequivocally
demonstrated that preoperative radiotherapy or chemoradia-
tion [12,13,20–23] is more effective than postoperative chemo-
radiation therapy in terms of reducing local recurrence, and
with less acute and late toxicity than postoperative therapy.
Yet the risk of dying from rectal cancer is linked mainly to
the development of distant metastases, and to experience a
late local recurrence as described by Sauer et al. [23] the pa-
tient needs to survive 5 years. As an alternative setting to con-
current chemoradiation (which only delivers 5–6 weeks of
chemotherapy), potential options are an induction compo-
nent of 6–12 weeks of neoadjuvant chemotherapy (NACT)
prior to radiotherapy or chemoradiation [20,24–27], adding
chemotherapy after SCPRTor chemoradiation (defined as con-
solidation chemotherapy) which utilises the ‘‘dead space’’ of
the interval between the end of chemoradiation and surgery
[28–30], or delivering chemotherapy alone without any radio-
therapy [31,32].
In Valentini’s recent pooled analysis of seven chemoradi-
ation trials, the most effective predictive model for
developing local recurrence was based on ypT stage, cT
stage, age, ypN stage and concomitant delivery of adjuvant
chemotherapy. Hence the only preoperative data available
were age and cT status. The best model for predicting
distant metastases used ypN stage, ypT stage, surgical
procedure and delivery of adjuvant chemotherapy (in order
of relevance). Hence these nomograms are unhelpful in the
preoperative setting [3].
More recently, outcomes have been shown to vary accord-
ing to predicted (i.e. clinical) T stage of disease (Table 1), and
other prognostic factors (mainly extramural vascular invasion
and tumour extent in relationship to the circumferential
resection margin), which can be determined by preoperative
magnetic resonance imaging (MRI). Hence a more individua-
lised approach to treatment selection is now feasible accord-
ing to the relative risk of local recurrence versus metastatic
disease. However, the consistently accurate parallels between
clinical imaging and pathological staging obtained in the
MERCURY study have not been easily reproduced. Both the
technical aspects and the immediate demands of the pres-
ence of a specialist radiologist for optimal MRI imaging, and
the interpretation of the scans, mean there is a significant de-
gree of individual variation between andwithin centres. All of
these factors have contributed to a variable acceptance of the
technique worldwide.
In this article for the ESMO educational symposium we
discuss the various available options for neoadjuvant therapy,
their rationale and the results obtained. We consider the dif-
ferent approaches of long-course CRT and SCPRT: the intensi-
Table 1 – Japanese-style surgery with laparoscopic pelvic lymph-node dissection (LPLND). Risk of local recurrence and distant
metastases. Cut-off for depth of mesorectal involvement 64 mm.
Stage IIA Stage IIIB All Stage III
64 mm Local recurrence 12/295 (4.1%) 14/204 (6.9%) 21/245 (8.6%)
Distant metastases 21/295 (7.1%) 36/204 (17.6%) 47/245 (19.2%)
>4 mm Local recurrence 13/295 (7.7%) 23/218 (10.6%) 34/267 (12.7%)
Distant metastases 28/168 (16.7%) 58/218 (26.6%) 75/267 (28.1%)
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dose-escalation of external-beam radiotherapy (EBRT), using
brachytherapy, intraoperative radiotherapy (IORT), hyperfrac-
tionation and various available techniques such as intensity-
modulated radiotherapy (IMRT). We make recommendations
as to which clinical or imaging features require preoperative
CRT or SCPRT to be delivered, and where it could possibly be
avoided. The strategies of neoadjuvant, concurrent, consoli-
dation (i.e. immediately following chemoradiation and prior
to surgery) chemotherapy with cytotoxic agents are explored.
We speculate on the initial attempts to integrate biological
agents as future potential strategies of treatment with and
separate from radiation.
The current era of precision imaging offers many options
for conformal external-beam radiotherapy, such as IMRT,
volumetric arc therapy (VMAT), brachytherapy and a pleth-
ora of systemically active cytotoxic and biological agents.
Practice has also been driven more recently by meticulous
refinements in surgical technique, in which all the sur-
rounding mesorectal fat are removed in a neat anatomical
package (total mesorectal excision and extralevator abdom-
inoperineal excision), the availability and quality of preoper-
ative MRI to determine potential risks, an increasing value
placed on histopathology and assessments/metrics of the
quality of surgery. TME is associated with much lower rates
of local recurrence and improved survival [4], but all these
advances have contained and driven down the local recur-
rence rate.
In 2005, investigators from Hong Kong challenged the ac-
cepted wisdom and questioned whether low-risk stage II pa-
tients benefit from neoadjuvant therapy [33]. With a median
follow up of 43 months, they reported a 6% local recurrence
rate at 5 years for patients undergoing anterior resection
(with a median level of tumour at 8 cm from the anal verge).
Recent population-based data [34] and retrospective series
exploiting these advances further undermine the approach
of a blanket use of radiotherapy/chemoradiation by exploring
the omission of radiotherapy when MRI suggests the tumour
is easily resectable and the circumferential resection margin
(CRM) is not threatened [35–38]. Others have also recently
questioned the routine use of chemoradiation for rectal can-
cer [39,40].
The current high clinical and pathological response rates
[41] observed from chemotherapy in small clinical trials also
offer an alternative option to chemoradiation. So the ratio-
nale for selecting patients suitable and appropriate for neoad-
juvant preoperative radiotherapy/chemoradiotherapy needs
reconsidering.For patients with resectable rectal cancer prior to the cur-
rent TME era, trials of CRT or SCPRT demonstrate a reduction
in loco-regional failure (LRF), but without extending DFS or
OS.
More recent randomised trials in locally advanced rectal
cancer (LARC) suggest that the high historical local recurrence
rate of the 1990s has been reduced to <10% with CRT and/or
SCPRT. In the main, local recurrence in rectal cancer has been
replaced by an even larger risk of metastatic disease as the
current predominant problem. Hence many oncologists have
recommended both intensifying chemotherapy in the neoad-
juvant setting, and also integrating other cytotoxic drugs, in
addition to 5FU, into CRT schedules as the logical next steps
to improve outcome in rectal cancer.
In the UK and Northern Europe patients with rectal cancer
are selected for preoperative treatment on the basis of clinical
staging. Many multidisciplinary teams categorise patients
into ‘‘the good, the bad and the ugly‘‘, which allows the defi-
nition of three different clinical settings for rectal cancer
[42]. Early cT1/T2 tumours are not usually treated with radio-
therapy; more advanced T3 tumours in which the patient is
considered at risk of local recurrence [15,43] are advised to re-
ceive SCPRT followed by TME; and thirdly patients, with clin-
ically unresectable cancers – where MRI suggests a
threatened/ breached CRM (10–15% of cases), or the levators
are potentially involved, or in cancers which require surgical
resection beyond the conventional TME plane – then radiation
as a component of CRT is clearly necessary for down-staging.
MRI assessment forms the basis of the recent UK 2011
NICE clinical colorectal guidelines on colorectal cancer
(http://guidance.nice.org.uk/CG/Wave16/2) which defines
three different risk groups of patients with rectal cancer,
according to the risk of local recurrence. MRI is sufficiently
sophisticated to allow accurate prediction of mesorectal sur-
gical margin involvement by tumour (within a tolerance of
1 mm) preoperatively, and can also demonstrate macro-
scopic extramural vascular invasion (EMVI). Both a positive
CRM and EMVI carry a high risk of subsequent metastatic
disease.
Few patients in any of the randomised phase III
studies had standardised staging with MRI. Few had primary
rectal cancers staged as T4 or, by MRI criteria, were
encroaching on, or extending beyond total mesorectal exci-
sion planes, which are considered to require preoperative
chemoradiation (and sometimes surgical resection beyond
conventional TME planes). Such poor-prognosis patients have
an even higher risk of metastatic disease even after success-
ful surgery.
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2.1. SCPRT
Several trials with more than 6000 patients support the bene-
fit of SCPRT in reducing local recurrence. The rationale for
SCPRT is based on the short overall treatment time (OTT),
which allows surgery to take place before the radiation reac-
tion is expressed, but does not allow sufficient time for tu-
mour shrinkage.
The Swedish Rectal Cancer Trial [13] randomly assigned
patients with cT1–3 rectal cancer to SCPRT and immediate
surgery versus surgery alone (not TME). A significant improve-
ment in both local recurrence and survival was observed in
the SCPRT arm. The Dutch group performed the Commissie
Klinisch Vergelijkend Onderzoek (CKVO) 95-04 trial, which
used the same design but trained and mandated surgeons
to perform TME. Both early [43] and more mature long-term
reports [44] confirmed a significant improvement in local con-
trol with SCPRT, although no difference in overall survival was
observed.
The MRC CR07 trial [6,15] randomised 1350 rectal cancer
patients to either SCPRT (5 · 5 Gy) followed by immediate sur-
gery or selective postoperative chemoradiation (25 · 1.8 Gy
with concurrent 5-fluorouracil) administered only for patients
with histologically involved (61 mm) resection margins. The
majority of resections were considered TME, but only 51%
were good quality TME in the mesorectal plane [6]. Overall,
clinically significant absolute risk reduction in the 3-year local
recurrence rate of 6.2% was observed (4.4% for SCPRT versus
10.6% for selective postoperative CRT), corresponding to a rel-
ative risk reduction of 61%. At 3 years, disease-free survival
was 6% better for SCPRT, but there was no improvement in
overall survival. The CR07 trial suggests SCPRT reduces the
risk of local recurrence for all tumour locations, all patholog-
ical stages, and good, average or poor quality surgery.
SCPRT may also only partially compensate for a positive
CRM [45,46] if this threat to the mesorectal fascia (MRF) was
not detected on preoperative MRI. This strategy has aims dif-
ferent from those of long-course CRT, where we hope to
shrink/down-stage the tumour and facilitate an R0 resection
to be performed, or to increase the chances of performing
sphincter-sparing surgery.
Other advantages of SCPRT include high compliance, even
in the elderly, and low cost. Two large randomised trials have
each reported that in resectable cancers, SCPRT and CRT are
equivalent in terms of outcomes such as local recurrence, dis-
ease-free survival (DFS) overall survival (OS) and toxicity
[16,17] (Table 2). In the UK, SCPRT is increasingly being used
with an interval to surgery or as a radical treatment ± high
dose rate brachytherapy (HDRBT). SCPRT is considered to
have the advantage of rapid delivery and high compliance
for patients who are frail, elderly and with cardiac and renal
co-morbidities which preclude 5FU-based chemotherapy.
However, there is a price to pay. Long-term data from ran-
domised trials of SCPRT versus surgery alone demonstrate al-
most twice the prevalence of bowel dysfunction after SCPRT
[47–50]. The CR07 data suggest that SCPRT caused a signifi-
cant increase in unintentional release of stools [51]. Morerecent retrospective analyses suggest that frequency, urgency,
evacuatory difficulties and faecal incontinence – i.e. the low
anterior resection syndrome (LARS) – are common. Effects
on sexual functioning [52] and urinary incontinence [49] have
also been documented after SCPRT.
With modern MRI, metabolic imaging with positron emis-
sion tomography/computed tomography (PET/CT) and indi-
vidual biomarkers it should be possible to be more selective
for risk of local recurrence. It is therefore difficult to support
the current widespread advocacy for routine adjuvant radio-
therapy as used in the treatment arms of recent trials. Alter-
natively for this same reason, efforts have been made to limit
the radiation dose to normal rectum.
The histology is only minimally corrupted by the radio-
therapy changes, allowing accurate pathological staging in
terms of the nodal status, extramural vascular invasion and
perineural invasion. Patients treated with SCPRT or HDRBT
will undergo surgical resection and receive postoperative
adjuvant chemotherapy many weeks earlier than with con-
ventional CRT. Hence selection for and delivery of postopera-
tive adjuvant chemotherapy with systemically active
schedules (e.g. FOLFOX) can usually start within 6–10 weeks
of diagnosis.
2.2. SCPRT and surgery after an interval
Two retrospective studies [53,54] reported safety and efficacy
of SCPRTwith an interval of several weeks to allow response.
Both reported similar curative resection rates and local con-
trol as after preoperative long-course CRT. Although the pop-
ulations of these studies varied, a pathological complete
response (pCR) was observed in 4/37 patients (11%) and 2/24
patients (8%), respectively, who underwent surgery after an
interval of a few weeks.
A randomised Polish study of 154 patients with locally ad-
vanced rectal cancer who were operated using TME between
1999 and 2006 examined the influence of the time interval be-
tween SCPRT and surgery on long-term OS and recurrence
rate [55]. Patients were randomised between SCPRT (5 · 5 Gy)
followed by surgery either 7–10 days or 4–5 weeks later after
completion of RT [55]. With approximately 4 years minimum
follow-up, 5-year survival rates were 63% and 73% for imme-
diate and later surgery respectively (P = 0.24). The longer time
interval between RT and surgery resulted in a greater down-
staging rate (44.2% versus 13%), but did not increase sphinc-
ter-saving procedures or curative resections.
A further small randomised trial of 83 patients with resect-
able (stage II and III) rectal cancer [56] compared the clinical
and pathological down-staging from SCPRT and long-course
CRT followed by surgery after an interval of 6 weeks in both
groups. The preliminary results suggested improved tumour
down-sizing from CRT compared to SCPRT. Pathological com-
plete response was observed in one patient (2.7%) in the
SCPRT group versus six patients (13.1%) in the CRT group.
Postoperative morbidity and R0 resection rates were similar.
The ongoing Stockholm III trial – which is randomising be-
tween three arms: SCPRT proceeding to immediate surgery
within a week, SCPRT and delayed surgery after 4–8 weeks,
and 50 Gy in 25 fractions with surgery after a similar interval
Table 2 – Trials comparing shortcourse preoperative radiotherapy (5X5 Gy) with preoperative chemoradiation.
Trial No Stage chemo Adjuvant
chemotherapy
Local
recurrence
RFS/DFS 5 year OS
Polish SCPRT 155 cT3-T4 none Optional Crude 9% 4 year DFS 58% 4 year OS 67%
Polish CRT 157 cT3-T4 5FU/FA Optional Crude 14% 4 year DFS 56% 4 year OS 66%
TROG SCPRT 163 II-III none Mandated
FUFA 6/12
3 years 7.5% 5 year RFS 64% 5 year 74%
TROG SCPRT 163 II-III PVI 5FU 225mg/m2 Mandated
FUFA 4/12
3 years 4.4% 5 year RFS 61% 5 year 70%
Latkauskas SCPRT 37 II-III none Not stated Not stated Not stated Not stated
Latkauskas CRT 46 II-III 5FU/FA Not stated Not stated Not stated Not stated
Pach 2012 SCPRT
immediate 7-10 days
77 I-III none Not stated 1.5% Not stated 63%
Pach 2012 SCPRT
delayed 4-5 weeks
77 I-III none Not stated 7% Not stated 73%
SCPRT = short course preoperative radiotherapy; CRT = chemoradiation; RFS/DFS relapse free survival/disease free survival; OS = overall
survival; FUFA = 5FU and folinic acid.
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interval for response after SCPRT. However, current data sug-
gest that it is feasible to use SCPRT and delay for several
weeks, opening the opportunity to fill this gap with chemo-
therapy. This strategy has been successfully employed in pa-
tients with synchronous metastases [58].
2.3. Chemoradiation
The rationale for long-course chemoradiation is to achieve
additive effects from the combination of chemotherapy and
radiation, both locally and systemically, with a concurrent
fluoropyrimidine, thereby inducing down-staging/downsiz-
ing, and in some cases facilitating sphincter-sparing proce-
dures, while at the same time reducing distant metastases
and in a small group of patients (approximately 10–15%)
achieving tumour sterilisation. The current shortcoming of
this approach is that we have only managed to integrate sin-
gle-agent fluoropyrimidines (intravenous 5FU or capecita-
bine/UFT) at suboptimal, sub-systemic doses into everyday
practice.
In ultrasound-staged resectable cancers (i.e. presumably
where the preoperative MRI would now suggest the CRM/
MRF is not potentially involved), or where down-staging is
not required, then SCPRT and CRT have been shown to be
equivalent in terms of outcomes such as local recurrence,
DFS and OS [17,18]. For more advanced cases, where the sur-
geon assesses the tumour as unresectable and/or the CRM/
MRF is recognised to have been breached or threatened
according to the MRI appearances, long-course CRTwith the
addition of 5FU to radiation has favourable effects on re-
lapse-free survival (RFS) and cancer-specific survival with a
trend to improve overall survival [59].
Concerns also remain that the delivery of adjuvant chemo-
therapy in the postoperative setting has frequently been com-
promised by delays because of surgical morbidity, slow
recovery and healing, poor tolerance, and marked dose reduc-
tions, with patient compliance being approximately 50%
[19,60,61]. These three studies showed that 20%, 23% and
25%, respectively, failed to start postoperative 5FU-based
adjuvant chemotherapy. The observation from Biagi et al.
[62] that even a few weeks delay following curative surgerybefore implementing systemic chemotherapy impacts on sur-
vival provides a rationale to administer chemotherapy
preoperatively.
Despite the above controversies, consensus guidelines
from European groups [63,64], Canada [65] and the United
States of America [66] recommend preoperative chemoradia-
tion for the majority of patients with stage II and stage III rec-
tal cancer. This approach has narrowed to the conventional
use of 45–50.4 Gy at 1.8 Gy per fraction, irrespective of the
stage, size, site and molecular biology of the cancer [67].
There are also significant long-term late effects, including
an increased risk of insufficiency fractures in the pelvis
[68,69], and an increased risk of second malignancies from
CRT even within 10–12 years. Tubiana [70] warns that large
target volumes treated with moderate doses carry a high risk
of second malignancy. The incidence of second malignancy
has probably been underestimated because, with a median
age of 65–70 years, patients in rectal cancer trials had a rela-
tively short life-expectancy after treatment, and follow-up is
usually short. With recent gains in survival, longer follow-
up, cancer registries and end-result programmes, the cumula-
tive incidence of secondmalignancies could reach as much as
20% of patients treated by radiotherapy [70].
2.4. Intensity-modulated radiotherapy (IMRT)
Clinical trials of SCPRT or CRT have almost invariably used
three- or four-field techniques. Acute gastrointestinal toxicity
is the commonest dose-limiting toxicity in many chemoradi-
ation trials, and provides the main dose-limiting factor for the
radiotherapy. In the German CAO/ARO/AIO-94 trial, preopera-
tive chemoradiation led to a 12% rate of G3–4 acute toxicity in
terms of diarrhoea, and a 9% rate of gastrointestinal G3–4 late
toxicity. Total doses of between 45 and 50 Gy probably lead to
a 5% risk of late toxicity for the small bowel at 5 years, and
there is a significant association between 6G3 acute small
bowel toxicity and the volume of small bowel irradiated [71–
74]. Acute toxicity in trials which have integrated oxaliplatin
have even higher rates of G3/G4 diarrhoea at approximately
25%, and might be expected to be associated with a greater
risk of late damage to the small bowel. None of the random-
ised phase III trials to date in rectal cancer have used IMRT.
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(MLCs) which can be adjusted during the treatment may limit
the radiation dose to the bowel and other normal structures,
thereby potentially reducing acute and late gastrointestinal
side effects [75–77]. A recent retrospective review demon-
strated a significant decrease in gastrointestinal toxicity
grade P2 for patients receiving IMRT [78]. We clearly need
to evaluate the precise mechanisms that are responsible for
the late functional effects of radiotherapy, as some patients
could either forego radiotherapy completely, or the radiother-
apy fields could be more tailored to avoid say the lumbarsa-
cral plexus or the sphincter mechanisms themselves.
Alternatively, IMRT/IGRT may facilitate EBRT dose-escala-
tion of radiotherapy protocols and more aggressive combina-
tions of radiotherapy with cytotoxic chemotherapy and/or
novel systemic agents. The downside is increased low-dose
exposure of the surrounding healthy tissue circumferentially
around the tumour, potentially leading to an increase in the
volume of normal tissues exposed to low doses of radiation.
IMRT with capecitabine and oxaliplatin is being tested in a
phase II study (RTOG 08-22) for cT3-4N0-2 patients with rectal
cancer. The preliminary results, presented in abstract form
only, appear to show that IMRT is feasible with a high rate
of contouring and planning compliance and less gastrointes-
tinal gradeP2 toxicity compared with other RTOG rectal can-
cer chemoradiation studies such as RTOG 0247 [79].
More recently several other strategies have been used to
increase the radiation dose to the primary with brachyther-
apy or contact boost, with intraoperative radiotherapy using
electrons.3. Brachytherapy
High-dose-rate intraluminal brachytherapy (HDRBT) is highly
conformal; the rapid fall-off in dose allows a high dose of radi-
ation to be delivered at themucosal surface of the rectumover-
lying the tumour and reduces doses to surrounding normal
structures compared to conventional radiotherapy tech-
niques. Publications are sparse for resectable rectal cancer,
and rely mainly on a single institution (McGill University in
Montreal) which has reported significant tumour regression
in over 300 patients, over 29% of the patients achieving a com-
plete pathological response at surgery [80–82]. Because of the
rapid dose fall-off, HDBRT may treat the pelvic lymph nodes
less adequately. Preoperative HDRBT (26 Gy over 4 days) fol-
lowed by surgery after 4–8 weeks compares favourably in
terms of complications and outcomes with SCPRT in a recent
matched retrospective analysis from Canada and Sweden
[83]. Brachytherapy also appears as effective as long-course
conventional CRT butmay be associatedwith less severe acute
toxicity. However, many radiation oncologists remain uncer-
tain about the late sequelae from use of higher dose rates.
There is a significant dose–response relationship for
tumour regression after preoperative CRT [84]. Recent reports
describe a 31% pCR and 83% achieving an R0 resection in 34
patients treated with 10 Gy HDRBT boost following down-
staging of potentially resectable rectal cancers with long-
course chemoradiotherapy [85]. For inoperable tumours,
HDBRT has been used to dose-escalate after chemoradiationto achieve a greater tumour response and facilitate a curative
resection [86]. A small randomised study (Lyon 96–02) sug-
gests that a higher dose achieves a higher rate of complete
clinical response, and hence increases the chance of sphinc-
ter preservation from 44% to 76% [87,88].
4. Integration of cytotoxic agents into the
neoadjuvant setting
The intentions of integrating oxaliplatin into the multimodal-
ity treatment are, first, to assess additional effects from pre-
operative neoadjuvant using oxaliplatin as a radiosensitiser,
to achieve greater tumour response, and to reproduce some
of the gains in survival achieved by cisplatin in chemoradia-
tion schedules in cervix cancer/head and neck cancer. Sec-
ond, the hope is to achieve systemic effects, since in
metastatic disease the addition of oxaliplatin to the combina-
tion of 5FU and folinic acid (FOLFOX) offers response rates in
the range of 50% [89]. Oxaliplatin also has a proven role in the
adjuvant setting in CRC.
There are two distinct philosophical approaches for inte-
grating oxaliplatin in rectal cancer. Radiation oncologists
aim to integrate oxaliplatin during radiotherapy as a radio-
sensitiser to increase response (usually at sub-systemic doses
for tolerability). In contrast, medical oncologists are designing
phase II/randomised phase II trials using systemically active
high-dose chemotherapy outside chemoradiation to reduce
micrometastases outside the pelvis.
Four randomised phase III studies – Action Clinique
Coordonne´es en Cance´rologie Digestive (ACCORD), STAR-01
and NSABP R04 and CAO/ARO/AIO-04 and PETACC-6 studies
– (Table 3) have compared preoperative chemoradiotherapy
using a combination of a fluoropyrimidine and oxaliplatin
with preoperative chemoradiotherapy using an intravenous
or oral fluoropyrimidine alone [91–95]. Early results from
these randomised phase III trials have not shown any
significant impact on early pathological response with the
exception of the German CAO/ARO/AIO-04 study.
The ACCORD trial, which compared capecitabine plus
oxaliplatin with capecitabine alone, showed no difference
in the pCR rate, which (unusually for a phase III) formed
the primary end-point (19.2% versus 13.9%, P = 0.09) [92,93].
The STAR-01 trial also showed no difference in the pCR rate
(15% versus 16%, P = 0.982.). Yet the percentage of patients
with pathological M stage was significantly lower in the
5FU-plus-oxaliplatin group (2% versus 11%, P = 0.014), sug-
gesting that addition of oxaliplatin to preoperative CRT
might have influenced the development of distant metasta-
ses. In contrast, the CAO/ARO/AIO-04 study showed an im-
proved pCR rate in patients receiving oxaliplatin (17%
versus 13%, P = 0.038) [96]. In addition, the PETACC-6 trial
randomised patients between preoperative RT (50.4 Gray in
25 fractions) with capecitabine alone and the same radiation
schedule with capecitabine + oxaliplatin (50 mg/m2). The
trial has completed accrual and results are awaited.
4.1. Irinotecan
Several phase II trials have suggested a potential benefit for
the addition of irinotecan to preoperative CRT. The random-
Table 3 – Short-term outcomes from randomised studies integrating oxaliplatin (OXA) as radiosensitiser.
outcomes STAR-01 ACCORD- 0405 CAO/ARO/AIO-04 NSABP R04 PETACC-6a
5FU379 OXA352 Cape293 OXA291 5FU624 OXA613 5FU/cape622 OXA631 5FU/cape547 OXA547
G3/G4
diarrhoea
4% 15% 3% 13% 8% 12% 7% 15% Not stated Not stated
ypCR 16% 16% 14% 19% 13% 17% 19% 21% 11% 13%
Ypn0 74% 71% 70% 72% 70% 72% Not stated Not stated Not stated Not stated
Ypn+ 26% 29% 30% 28% 30% 28% Not stated Not stated Not stated Not stated
CRM <1mm 7% 4% 13% 8% 6% 5% Not stated Not stated Not stated Not stated
R0 resection 94% 97% Not
stated
Not
stated
92% 90% Not stated Not stated 92% 86%
5FU, 5-fluorouracil; CRM, circumferential resection margin.
a Ref. [90]
E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 4 5 –5 9 51ised phase II RTOG-0012 trial showed no benefit [97,98]. The
current national trial in the UK (ARISTOTLE) is examining
the utility of the incorporation of irinotecan into preoperative
CRT in MRI-defined unresectable/borderline resectable rectal
cancer (www.controlled-trials.com/ISRCTN09351447).
4.2. Integration of biologicals
Standard chemotherapy regimens for CRC have integrated
molecularly targeted agents (cetuximab, panitumumab, bev-
acizumab and aflibercept) to improve response rates or extend
PFS and OS. The approach of using epidermal growth factor
receptor (EGFR) and vascular endothelial growth factor (VEGF)
inhibitors has been extrapolated to the treatment of locally
advanced rectal cancer to avoid overlapping toxicities. Yet
the reader should be mindful that there is only a single phase
III study in any disease site demonstrating an advantage to
combined biological agents and radiotherapy compared with
radiation alone [99]. Also these agents have not been shown
to have activity in the adjuvant setting [100,101].
Bevacizumab added to standard cytotoxic chemotherapy is
associated with improved survival and higher pathological re-
sponse rates in patients undergoing resection of colorectal li-
ver metastases [102], but may not affect response rates
defined by RECIST (response evaluation criteria in solid tu-
mours) [103]. Bevacizumab may be safely administered in the
preoperative setting for the treatment of liver metastases
[104], without increasing post-surgical complications [105,106].
A phase I clinical study of bevacizumab prior to and con-
currently with 5FU-based CRTreduced tumour perfusion, vas-
cular volume, microvascular density, interstitial pressure and
viable endothelial cells [107]. Willett and colleagues continued
into a phase I/II study and reported a pCR rate of 16%, and an
additional 72% of patients who had only microscopic foci
remaining after treatment with bevacizumab and 5FU plus
RT in patients with T3/T4 tumours [108].
In another small phase I study in patients with metastatic
(four) or locally advanced rectal adenocarcinoma (seven), the
combination of bevacizumab, oxaliplatin and capecitabine
chemoradiation was active with a pCR of 22%, but with signif-
icant acute toxicity [109].
In a phase II study in patients with T3/4, N1, or recurrent
disease, administration of capecitabine and bevacizumab con-
comitant with preoperative RT resulted in a pCR rate of 32%
and amicroscopic residual disease rate of 24% [110]. A slightlylower pCR rate of 24% was observed in a phase II study of pa-
tients with T3/4N0 or T1-4N1-3 rectal cancer who received
induction CT comprising only two cycles of 5FU/LV + oxalipla-
tin (FOLFOX6) plus bevacizumab, followed by concomitant RT
plus FOLFOX and bevacizumab [111]. In this study 9/25 pa-
tients (36%) also developed postoperative complications [111].
The more recent AVACROSS study selected 47 patients
according to MRI criteria, and used four cycles of induction
chemotherapy using capecitabine, oxaliplatin and bev-
acizumab, followed by chemoradiation with concurrent cape-
citabine and bevacizumab [112]. Results are impressive, with
98% having an R0 resection and 36% achieving a pCR, while
a further 23% were down-staged to ypT1/T2N0. There was
one sudden death during the induction, and surgical morbid-
ity appears prominent, since 26/45 patients (58%) experienced
at least one postoperative complication and 11/45 (24%)
required surgical re-intervention (even though the median
time from the last dose of bevacizumab to surgery was
2 months).
A phase II trial evaluated preoperative capecitabine, oxa-
liplatin and bevacizumab with radiation therapy followed by
surgery and postoperative 5FU, leucovorin, oxaliplatin (FOL-
FOX) and bevacizumab for locally advanced rectal cancer in
57 patients [113]; 17% achieved a pCR, but 47% of patients
who underwent surgery experienced a surgical complication.
A Canadian study achieved a pCR of 18%, but four patients
(11%) required re-operation due to complications [114].
A further study evaluating bevacizumab/chemoradiation in
thepreoperativeandadjuvant settings in66patientswithstage
II/III rectal cancer [115] achieved a pCR rate of 29%, but again
showed frequent grade 3/4 toxicity and surgical morbidity.
None of these studies showed a consistent definitive signal
of improved efficacy. Yet, since the eligibility criteria in the
AVACROSS study, which achieved a pCR of 36%, were similar
to those of the GEMCAD study [116], where a pCR of only 14%
was observed with induction Xelox and capecitabine and oxa-
liplatin chemoradiation, it is possible that the addition of bev-
acizumab offers greater efficacy. However, several studies
raise concerns that the combination of bevacizumab and
radiation may impact on surgical morbidity. Future studies
need either to leave a longer interval following the comple-
tion of bevacizumab before surgery or to drop the bev-
acizumab from the chemoradiation component.
Preliminary results of chemoradiation clinical trials with
cetuximab, on the early clinical endpoint of pCR, are at best
52 E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 4 5 –5 9disappointing. A large multinational randomised phase II
study EXPERT-C (NCT00383695) has compared neoadjuvant
therapy comprising oxaliplatin, capecitabine and chemora-
diotherapy with or without cetuximab in 164 patients.
Kras status (mutant or wild-type) does not appear to be
predictive for pCR in rectal cancer when EGFR inhibitors are
integrated into chemoradiation regimens [117,118]. In the
more recent Expert C study, in the group of patients with
wild-type Kras, who received capecitabine, oxaliplatin and
cetuximab, the overall survival at 3 years was 96% [119].5. Chemotherapy additional to SCPRT or CRT
As an alternative setting to concurrent chemoradiation
(which only delivers 5–6 weeks of chemotherapy) potential
options are either an induction component of 6–12 weeks of
NACT prior to radiotherapy or chemoradiation [24–26], adding
chemotherapy after SCPRT or chemoradiation as consolida-
tion, which utilises the ‘‘dead space’’ of the interval between
the end of chemoradiation and surgery [28,30], or delivering
chemotherapy alone without any radiotherapy [31,32].5.1. Neoadjuvant/induction chemotherapy prior to
chemoradiation
The most popular method of integrating chemotherapy is as
induction prior to chemoradiation, which achieves high rates
of symptomatic improvement (65%) [120]. Clinical response
rates with induction chemotherapy vary between 28% [120],
41% [27] and 59% [119] when cetuximab was added, with no
patients observed to have progressive disease.
Phase II randomised studies [25,116,119,121] suggest that
neoadjuvant chemotherapy prior to chemoradiation is feasi-
ble, and can be delivered with minimal compromise of either
the radiation or subsequent surgery.
The EXPERT phase II study of 78 patients used a 12-week
induction phase of capecitabine and oxaliplatin followed by
chemoradiation with capecitabine with chemoradiation (total
dose 54 Gy) in locally advanced rectal cancer. The radiological
response rate was 81% (two CRs and 50% PRs). The early out-
come results of this study appear impressive, but it is not pos-
sible to determine the relative contributions of the induction
chemotherapy and the concurrent CRT schedule or the high
dose of pelvic radiotherapy (54 Gy); however, when compared
to the group’s subsequent study, with an identical eligibility
and chemotherapy schedule but a lower RT dose (50.4 Gy),
the pCR fell from 23% to 14% [119]. Mature results of the EX-
PERT trial in 105 patients [25] demonstrated a 3-year PFS
and OS of 68% and 83% respectively. The 3-year RFS for the
93 patients who had a R0 resection was 74%.
A Spanish study (GCR-3 study) compared a conventional
schedule of chemoradiation followed by TME and postopera-
tive adjuvant chemotherapy using capecitabine and oxalipla-
tin, against induction chemotherapy using capecitabine and
oxaliplatin followed by CRT and TME [116]. The pCR rate
was similar in both arms, 14% versus 13%, but significantly
more patients in the postoperative adjuvant arm had grades
3/4 acute toxicity than in the induction arm (54% versus
19%; P = 0.0004, respectively). In the postoperative adjuvantarm, 25% of patients did not begin treatment, and only 51%
received all four cycles, whereas 100% of patients in the
induction arm began treatment, and 92% received all four
(P = 0.001). The relative dose intensity for both capecitabine
and oxaliplatin were significantly higher in the induction
arm, with no differences in radiotherapy compliance between
the two arms (P = 0.001). Despite the high compliance in the
induction arm, 3-year DFS was not increased [121].
The NASBP-R-03 (National Surgical Adjuvant Breast and
Bowel Project R-03) is the only phase III trial to have inte-
grated neoadjuvant chemotherapy at systemic doses. The
trial randomised 267 patients to either preoperative 5FU
based CRT (n = 130) or postoperative CRT (n = 137) [20]. In addi-
tion, the preoperative arm utilised up-front weekly bolus 5FU/
leucovorin (LV) for 6 weeks prior to starting concurrent CRT
(5FU/LV for 5 days during the first and fifth weeks of radiation
to a total dose of 45 Gy with a 5.4 Gy boost). Thus the trial
mandated 3 months of neoadjuvant 5FU/LV in the preopera-
tive arm, followed by postoperative adjuvant weekly 5FU/LV.
The accrual was lower than expected (267 of the planned
900 patients). The preoperative treatment arm failed to dem-
onstrate an improvement in local recurrence. The 5-year
cumulative incidence of locoregional recurrence was 10.7%
for both treatment arms (HR = 0.86; 95%CI, 0.41–1.81;
P = 0.693), but had a statistically improved DFS with a hazard
ratio of 0.629 (P = 0.011) and a trend towards improved overall
survival. These findings suggest an effect of the neoadjuvant
chemotherapy on systemic disease.
In the CONTRE trial, patients received eight cycles of FOL-
FOX as NACT followed by CRT and surgery. Preliminary data
presented at the Gastrointestinal American Society of Clinical
Oncology (GI ASCO) 2013 meeting from the first 32 patients re-
ported a 33% pCR rate and >90% compliance [122].
A recent study with induction FOLFOX and bevacizumab
[111] provoked grade 3/4 toxicity during chemoradiation in
19 of 25 patients (76%). In some of these phase II studies the
authors do not clearly report the toxicity profiles separately
for concomitant chemoradiation and when used as full-dose
chemotherapy alone [28]. However, studies of neoadjuvant
chemotherapy raise concerns regarding the high rate of toxic
deaths. Patients with the more advanced and larger pelvic tu-
mours appear to have a particularly high risk of thromboem-
bolic and cardiac effects [25,123], less so if T4 tumours are
excluded [31].
5.2. Consolidation chemotherapy (neoadjuvant
chemotherapy following chemoradiation)
Consolidation chemotherapy does not compromise compli-
ance to and delivery of chemoradiation. Retrospective data
from the Memorial Sloane Kettering Cancer Center [124] and
others [125,126] suggest that increasing the interval between
CRT and surgery might enhance the rate of pathological com-
plete responses, although other studies partly contradict this
[127,128].
Habr-Gama reported that extending the duration of the
chemotherapy post-chemoradiation increased the complete
clinical response rate (cCR) of 48%, achieving an overall com-
plete response rate (i.e. including cCR and pCR) of 65% [27].
Recent studies have tested the hypothesis that by delaying
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54 E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 4 5 –5 9surgery or increasing the interval between CRT and surgery,
and allowing more time for response or even administration
of two additional cycles of FOLFOX chemotherapy, it may be
feasible to increase down-staging and achieve a higher rate
of pCR [29,122].
The ‘Timing of Rectal Cancer Response to Chemoradiation
Consortium’ phase II multicentre trial used NACT as consoli-
dation chemotherapy in the interval following CRT prior to
surgery, with pCR as the primary endpoint. An initial cohort
preserved the standard 6–8 week interval between comple-
tion of CRT and surgery, which achieved a pCR of 18%.
Sequential cohorts added further cycles of consolidation FOL-
FOX after CRT prior to surgery, increasing the pCR rates to 25%
and 30%, respectively [29]. Postoperative adjuvant FOLFOX
chemotherapy was also administered to achieve a total of
6 months of systemic chemotherapy.
The delay in surgery by leaving the primary in situ could
potentially increase the chance of metastatic disease. A fur-
ther question remains as to whether FOLFOX is as effective
at preventing metastatic disease if the primary (with pre-
sumed stem cells) remains in situ when the chemotherapy
is interrupted and attenuated by delivery in a few cycles
rather than as a continuous 3–6-month treatment.
5.3. Neoadjuvant chemotherapy without chemoradiation
Neoadjuvant chemotherapy may achieve better access to
malignant cells when the tumour has an intact blood supply,
and may offer better compliance to treatment [116]. Systemic
doses of chemotherapy can be delivered at an early stage of
the diagnosis rather than after a delay of up to 18 weeks asso-
ciated with standard CRT. Two studies from the Memorial Slo-
an-Kettering Cancer Center support the feasibility of
neoadjuvant chemotherapy alone in rectal cancer [31,32].
This feasibility study in patients with clinical stage II–III [31]
rectal cancer (but not T4 tumours) used FOLFOX (oxaliplatin
and 5-flourouracil) with bevacizumab [31] The R0 resection
rate was the primary outcome. They reported a pCR in 8/29
patients (27%).6. Trials in progress (Table 4)
A Polish study (NCT00833131) in unresectable rectal cancer
addresses the question of whether SCPRT (25 Gy in 5 frac-
tions) followed by consolidation chemotherapy using FOL-
FOX4 can increase the rate of R0 resection compared with
the standard of conventionally fractionated chemoradiation
(50.4 Gy total dose in 28 fractions of 1.8 Gy over 5.5 weeks with
FULV or capecitabine).
A similar study (RAPIDO) is a collaboration of Dutch and
Swedish study groups and compares chemoradiation
followed by delayed surgery and postoperative adjuvant che-
motherapy with 5 · 5 Gy SCPRT followed by chemotherapy
and then followed by surgery.
The present authors are participating in a randomised
phase II neoadjuvant study (BACCHUS (Bevacizumab and
Combination Chemotherapy in Rectal Cancer until Surgery)
in resectable rectal cancer where preoperative MRI suggests
adverse features such as EMVI, but the CRM is not threatened.
E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 4 5 –5 9 55The study aims to evaluate the efficacy, toxicity and feasibility
of FOLFOX/ bevacizumab versus FOLFOXIRI/ bevacizumab.
7. The future
Many questions regarding the role of neoadjuvant chemother-
apy remain. In CRC, as in other malignancies, combination
cytotoxic chemotherapy is more effective in improving sur-
vival, so is the current standard of 5FU or capecitabine the
optimal partner to radiotherapy in preoperative CRT? Is the
theoretical benefit of additional agents such as oxaliplatin
outweighed by the increase in acute toxicity, or disguised/di-
luted by the short-term duration of weeks rather than
months and the failure of current regimens to achieve sys-
temically active doses? Is there a role for altered fractionation
in conjunction with concurrent chemotherapy? Should we
integrate targeted therapies into CRT or will we find antago-
nism as with the combination of EGFR and VEGF inhibition
and chemotherapy? Can we reduce the acute and late toxicity
of CRT with improvements in RT delivery such as IMRT/
VMAT?
Finally, is disease stage (i.e. cTN) the best way to select for
SCPRT/ CRT treatment? Can we identify patients more or less
likely to benefit from preoperative CRT, in terms of defining
either patients with a particularly low risk of local recurrence
who do not require RT, or patients with a particularly high risk
of metastatic disease for whom pelvic RT is probably irrele-
vant [43].
8. Conclusion
There is strong evidence for the role of radiotherapy in reduc-
ing the risk of local recurrence. Radiotherapy remains an
important component of the multimodal treatment of rectal
cancer, particularly if the CRM is threatened. The two current
routinely administered (and evidence-based) different ap-
proaches (SCPRTand neoadjuvant CRT) are supported by large
randomised phase III trials, and are now endorsed and widely
used for resectable rectal cancer (T3–T4 or N+). However, rou-
tine use and support for both approaches is not universal.
Individual radiation oncologists often favour one or other of
these approaches. Arguments usually address the risk of local
recurrence, enabling a curative resection and facilitating
sphincter-sparing surgery, rather than the integration of sys-
temic chemotherapy and the high risk of metastatic disease.
However, CRT has found favour because of the opportunity
for response and down-staging and even complete patholog-
ical response.
To increase tumour resectability, there is scope for escalat-
ing the dose of radiation – particularly to the area where the
CRM is threatened on MRI – either with HDRBT or the
opportunity for dose-painting with IMRT. For less advanced
cases, where the CRM is not threatened, the risk of metastatic
disease now predominates over the risk of local recurrence.
To reduce metastases, systemically active cytotoxic chemo-
therapy with or without biological agents is clearly required.
Chemotherapy at systemically effective doses is therefore a
logical way to improve survival in patients with locally ad-
vanced rectal cancer. Concurrent, induction, and consolida-
tion chemotherapy prior to surgery are all potentialstrategies for improving outcome. Trials are required to as-
sess the role of chemotherapy both with and without
radiotherapy.
Increasing surgical precision and a greater recognition of
the long-term functional effects of radiotherapy and the risks
of second malignancy have reduced local recurrence, and
prompted a more selective use of neoadjuvant radiotherapy
treatment based on MRI-derived risk. Treatment choices for
the individual should now reflect the surgeon’s and multidis-
ciplinary team’s views on a more realistic balance between
the relative importance of preventing local recurrence, the
adverse impact of radiotherapy on function and quality of life,
the avoidance of a permanent stoma and the more predomi-
nant risks of metastastic disease.
In the future imaging and biomarkers will increasingly
predict the risk of local recurrence, metastatic disease, and
those patients more likely to suffer severe late effects from
radiotherapy, and thus help to individualise treatment.Conflict of interest statement
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